Connect with us

News

Experts ‘not surprised’ by England’s stark maternal health disparities

Black women have historically faced racism and mistreatment at the hands of medical professionals, campaigners have said

Published

on

Experts have said they are not surprised by England’s “stark” maternal health disparities after a new report has shed light on the reality many Black mothers across the nation are facing.

An analysis conducted by the Guardian found that Black women are up to six times more likely to experience some of the most serious birth complications during hospital delivery across England than their white counterparts.

Black women made up 26 per cent of the women who experienced the birth complication preeclampsia superimposed on chronic hypertension during delivery, the report showed, despite making up just five per cent of all deliveries across England.

However, the findings have come as no surprise to experts who said Black women and women of colour had historically faced racism and mistreatment at the hands of medical professionals.

“The Guardian’s analysis, which starkly highlights the severe disparities in birth complications amongst Black women, is deeply concerning, yet sadly predictable,” Agnes Agyepong, maternal health advocate and founder of Global Black Maternal Health, told Femtech World.

“Systemic and structural issues, such as disparities in healthcare access, quality of care, and exacerbated underlying chronic conditions due to socio-economic and environmental factors, play a significant role. These barriers mean that when Black women voice their concerns early on, they are often not heard, leading to delayed or less effective antenatal care and poorer outcomes.”

Without tackling these structural inequities, and without taking a biopsychosocial approach to maternity care, any long-term structural change remains a distant hope, Agyepong said.

Emily Butterworth, lead midwife at Lansinoh, said the “unfortunate reality” is that across England women’s ethnic background and socioeconomic status are strongly related to their likelihood of experiencing birth complications.

“To make pregnancy and birth safer we need a multifaceted approach, not only by midwives and obstetricians but also by public health professionals and politicians,” she explained.

“It is vital that we are raising awareness and training not only midwives and maternity professionals, but any health professionals who are caring for women before pregnancy and after pregnancy on cultural competency, and looking at ways we can eliminate implicit bias racial stereotyping.”

As part of efforts to reduce birth complications for minority groups and improve maternity care for all, Butterworth said we must address the roles of racism and discrimination in healthcare.

“Making birth safer for all will only be realistically achieved if we address the disparities in maternal health across the spectra of socio-economic backgrounds,” she said.

Black women in the UK are almost four times more likely to die in pregnancy and childbirth than their white counterparts, while black babies are twice as likely to be stillborn.

Emma Jarvis, founder and CEO of pregnancy subscription service Dearbump, said this is due to the fact that Black women are less likely to seek support and less likely to be offered treatment.

“If you are treated poorly and your pain is not taken seriously you lose faith and trust in the system, and it’s hard to break that cycle.

“There needs to be a conscious effort from healthcare providers, policy makers and women’s health organisations, to proactively engage with and check in with Black mothers, and to be aware of any unconscious biases that might exist and recognise the heightened risk they face in maternal outcomes.”

Empowering Black and Brown women in healthcare settings should be a priority, said Wendy Powell, founder and CEO of maternal pelvic health platform MUTU System.

“Black and Brown women experience disproportionate adverse birth outcomes due to ingrained prejudices dictating their treatment and care levels,” Powell told Femtech World.

“However, it’s crucial to recognise the presence of implicit biases and systemic racism within healthcare systems and create environments where Black and Brown women’s voices are heard.

“By challenging bias and advocating for change, we can amplify the voices of marginalised communities and work towards a healthcare system that serves everyone.”

Dr Ranee Thakar, president of the Royal College of Obstetricians and Gynaecologists, called on the government to set a definitive target to eliminate racial disparities in maternal deaths.

“Whilst the college continues to deliver quality improvement programmes in maternity, it is crucial that the government commits to sufficient, long-term NHS investment for staff recruitment, retention and training, which underpins safe and compassionate care,” she said.

“We are also calling for the government to commit to a funded, time-limited target to end the higher risk of maternal mortality among Black, Asian and ethnic minority women, and for women living in more deprived area.”

Bliss, the UK’s charity for babies born premature or sick, called for more research into maternal morbidity and preterm birth.

“We know that the higher rates of birth complications for Black and Asian women are likely to be just one of the reasons they experience higher rates of preterm birth and are therefore more likely to have a baby admitted to neonatal care,” Caroline Lee-Davey, chief executive of Bliss, said.

“This is an unacceptable disparity, yet we still know so little about the reasons underlying these serious inequities in care. Bliss would like to see more research funded which specifically looks at these issues to inform improvements in care for both pregnant women and new-born babies from the Black and Asian community.

“We also urge health services and professional bodies to ensure that all maternity and neonatal health professionals have access to training and guidance that will specifically enable them to support Black and Asian parents and their babies, to stop them being unfairly and avoidably disadvantaged by current practice, and to ensure every baby has the best chance of survival and quality of life.”

To receive the Femtech World newsletter, sign up here.

Diagnosis

FDA approves AstraZeneca breast cancer drug

Published

on

The FDA has granted accelerated approval to AstraZeneca drug Etcamah for certain adults with advanced breast cancer carrying an ESR1 mutation.

Etcamah, also known as camizestrant, was approved in combination with a CDK4/6 inhibitor, either abemaciclib, palbociclib or ribociclib.

The treatment is for adults with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer when an estrogen receptor-1 (ESR1) mutation is detected during aromatase inhibitor and CDK4/6 inhibitor therapy using an FDA-authorised test.

ESR1 mutations are acquired resistance mutations that tumours may develop during treatment with aromatase inhibitors, a type of endocrine therapy commonly used as a front-line treatment for locally advanced or metastatic breast cancer.

Fewer than 5 per cent of patients have the mutation when HR-positive metastatic breast cancer is diagnosed, according to the FDA. After disease progression on an aromatase inhibitor, nearly 40 per cent have the mutation.

Acting FDA commissioner Kyle Diamantas said: “Women living with metastatic breast cancer face an uphill battle as their tumors continuously evolve to escape treatment.

“We owe them every weapon in our arsenal.

“Today’s approval delivers a win to these patients by granting them a targeted therapy designed specifically to overcome resistance, giving them more time before their disease progresses.”

The accelerated approval programme allows earlier approval of drugs that treat serious conditions and fill an unmet medical need based on surrogate or intermediate endpoints.

For Etcamah, approval was based on how long patients lived without their disease worsening, measured from when the resistance mutation was first detected in their blood.

The FDA said it has not yet been confirmed whether intervening when the mutation is detected, rather than waiting until disease progression is confirmed, results in a clinically meaningful benefit. Confirmatory studies are therefore required to verify and describe clinical benefit.

Angelo de Claro, director of the FDA’s Oncology Center of Excellence, said: “I commend both the FDA and the sponsor for their commitment to advancing cancer care and securing this accelerated approval.

“This marks the first FDA approval of a cancer therapy guided by the detection of a resistance mutation in circulating tumor DNA (ctDNA) before imaging tests show that the disease is progressing.

“But additional evidence is needed to confirm clinical benefit.”

Circulating tumour DNA, or ctDNA, consists of small pieces of tumour DNA released into the blood and can allow earlier molecular detection of resistance mutations.

The FDA also authorised the Guardant360 CDx assay as a companion diagnostic to identify patients with breast cancer who have ESR1 mutations for treatment with camizestrant.

Efficacy was assessed in a clinical trial comparing a switch to Etcamah plus a CDK4/6 inhibitor with continued treatment using an aromatase inhibitor plus a CDK4/6 inhibitor.

Estimated median progression-free survival was 16 months in the Etcamah group, compared with 9.2 months in the aromatase inhibitor group.

Etcamah’s prescribing information includes a boxed warning about the risk of irregular heart rhythm when taken with certain other medicines. It also includes warnings about an abnormally slow heart rate and potential harm to an unborn baby.

The FDA convened its Oncologic Drugs Advisory Committee for the application on 30 April 2026.

Continue Reading

Sponsored Content

Last chance to save on Women’s Health Week and Women’s Sport Summit: Early Bird pricing ends 11 September

Published

on

Early bird pricing for W Group’s two flagship October summits – Women’s Health Week Europe 2026 and Women’s Sport Summit Europe 2026 – closes on 11 September.

Both events take place at Emirates Stadium, London, bringing together founders, investors, corporates, and industry leaders shaping the future of women’s health and sport.

Women’s Health Week Europe 2026

7-8 October | Emirates Stadium, London

This year’s edition will be Women’s Health Week Europe biggest one yet: with 700+ attendees, 80+ speakers, and 20+ sponsors, it will also feature two stages – a Global Stage covering market trends and policy, and a Scale Stage focused on company-level growth and commercialisation. WHW takes place across two days of content, business matchmaking, and dealmaking.

Agenda highlights include:

  • Where Capital Flows: Funding Trends in Women’s Health – with Merete Clausen (EIF), Ekaterina Gianelli (Calm/Storm), Henriette Hessen (Verdane), Jemma Day (British Business Bank), Ravit Warsha Dor (Telus Global Ventures), Tim Davis (LSEG)
  • Six Feet Under-funded: Surviving the Valley of Death in Women’s Health – with Patric Stenberg (Gesynta Pharma), Valentina Milanova (Daye), Amber Vodegel (28x)
  • The Women’s Health Label – Gift or Curse? · Live Debate – with Juan Camilo Arjona Ferreira (organon), Marissa Fayer (DeepLook Medical), Christian Lautner (Heal Capital), Annie Theriault (CBIV), Ida Tin (Clue)
  • Passport to Scale: Taking Your Women’s Health Business Global – with Vanessa Carpenter (Femtech Across Borders), Annie Theriault (CBIV), Victorine Lançon (Daya Ventures), Dr Mridula Pore (Peppy)

Early bird pricing (ends 11 September):

Ticket typeEarly birdStandard
Startups, Scaleups, Investors, Non-Profits, Government£599 + VAT£699 + VAT
Corporates, Payors & Providers£1,799 + VAT£1,999 + VAT
Service Providers & Consultants£3,299 + VAT£3,499 + VAT

Register for Women’s Health Week Europe | See the full agenda for WHW

Women’s Sport Summit Europe 2026

6 October | Emirates Stadium, London

The first-ever Women’s Sport Summit expands W Group’s expertise in connecting key decision-makers to the sports industry.

WSS brings together rights holders, brands, investors, athletes, and media to accelerate commercial growth across the sector.

Agenda highlights include:

  • From capital to crowd: the women’s sport cycle at scale – with Omar Shaikh (Arsenal FC), Nicole McWilliams (Google), Kerstin Lutz (Mercury13), Jo Currie (BBC Sport)
  • Women’s sport through the investor lens: what gets funded – and why – Hugo Sever (APEX Capital)
  • Rethinking ROI: what are we measuring that doesn’t actually matter? – Fi Watherston (Metro Bank), Silvia Keiser (Billie Jean King Cup), Gabriel Akin-Odujobi (Crux Football), Tammy Parlour (WST)
  • Beyond the 90 minutes: matchday as a commercial product, not just a fixture – Maggie Murphy (Aston Villa Women FC), Sam Feasey (Diageo/Guinness), Molly Miller (OneFootball), Megan Feringa (The Athletic/The New York Times)

Early bird pricing (ends 11 September):

Ticket typeEarly birdStandard
General Pass£299 + VAT£399 + VAT
Service Providers & Consultants£1,799 + VAT£1,999 + VAT

Register for Women’s Sport Summit Europe | See the full agenda for WSS

Attending both events?

For group tickets or to attend both summits this October, contact Callum, W Group’s Client Success Lead, at [email protected].

Continue Reading

Mental health

Women more likely than men to get health advice from influencers, study finds

Published

on

Young women are more likely than young men to get health and wellness information from social media influencers, a US survey has found.

Among adults aged 18 to 29, 57 per cent of women said they received health and wellness information from influencers, compared with 47 per cent of men.

The Pew Research Center study surveyed 5,023 US adults and examined how young people consume health and wellness content online.

Local university students said influencer content frequently appeared in their social media feeds.

Kabija Koroma, a local university student, said: “It’s more exercise stuff, more like protein and like meals and like how to get ready and like the outfits of the day of videos on TikTok or lately. My favourite ones.”

About 51 per cent of women under 30 said they often consumed influencer content focused on beauty and personal appearance, compared with 18 per cent of men.

The study also found that 21 per cent of women often saw content about therapies outside mainstream medicine, compared with 10 per cent of men.

At least one-third of both young women and young men often encountered influencer content about mental health and weight loss. Around half or more of both groups regularly saw fitness-related content.

Another local university student, Ania Davis, said: “I see a lot like how to meal prep and how to get your morning started. Affirmations stuff. But I do also ask the adults around me because sometimes the internet is not right.”

Researchers also looked at why young adults sought health and wellness information from influencers.

About 51 per cent of young women said they watched the content because they wanted to change their health or lifestyle.

Women were also more likely than men to say they enjoyed hearing from people who shared their background or beliefs, at 23 per cent compared with 14 per cent.

Nineteen per cent of young women said they used influencer content to learn about topics they did not want to ask their doctors about, compared with 10 per cent of young men.

Despite regularly using social media, some students said they did not rely solely on influencer content when making decisions about their health and wellness.

Koroma said: “I’m always on TikTok 24/7 and Instagram, but I also like to ask people older than me because I don’t know everything.”

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.